Status:
COMPLETED
HCC Screening Using DNA Methylation Changes in ctDNA
Lead Sponsor:
HKGepitherapeutics
Collaborating Sponsors:
International Centre for Diarrhoeal Disease Research, Bangladesh
Conditions:
Hepatocellular Carcinoma
Eligibility:
All Genders
18+ years
Brief Summary
Hepatocellular Carcinoma (HCC) is the fifth most common cancer world-wide. It is particularly prevalent in Asia, and its occurrence is highest in areas where hepatitis B is prevalent, indicating a pos...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Confirmed diagnosis of HCC by EASL-EORTC guidelines
- Confirmed hepatitis B diagnosis for HepB patients using AASLD practice guidelines.
- Exclusion Criteria for HCC:
- Cirrhosis, any other known inflammatory disease (bacterial or viral infection with the exception of hepatitis B or C, diabetes, asthma, autoimmune disease, active thyroid disease) which could alter T cells and monocytes characteristics
- Other cancers.
- Exclusion Criteria for HepB:
- Diagnosis of HCC or any other cancer.
- Exclusion Criteria for Healthy Controls:
- Any known inflammatory or infectious disease including HepB and HepC
- Chronic diseases,
- Cancer
- Medications or drug use
Exclusion
Key Trial Info
Start Date :
August 20 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 1 2020
Estimated Enrollment :
403 Patients enrolled
Trial Details
Trial ID
NCT03483922
Start Date
August 20 2018
End Date
November 1 2020
Last Update
July 5 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Infectious Diseases Division
Dhaka, Bangladesh